Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE in ESRD
NCT02437422Phase 1Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Sanguinate in end stage renal disease (ESRD), sponsored by Prolong Pharmaceuticals. Primary endpoint: Safety of study treatment at 90 days. Started Jun 2015; status: completed.
02
Drugs
Sanguinate
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT02437422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437422.